US EditionUS authorizes first home test for three common sexually transmitted infections
- The U.S. Food and Drug Administration has approved the first-ever at-home test kit for chlamydia, gonorrhea, and trichomoniasis, which can be used without a prescription.
- The Visby Medical Women's Sexual Health Test accurately identifies chlamydia, gonorrhea, and trichomoniasis and shows results on a connected app in about 30 minutes.
- Courtney Lias from the FDA stated that expanding access to at-home STI testing is crucial for diagnosing and treating infections.
- In 2023, there were over 1.6 million reported cases of chlamydia and 601,319 cases of gonorrhea in the U.S., highlighting the importance of accessible testing.
74 Articles
74 Articles
iosconews.com
FDA Approves First At-Home Test to Diagnose Three STIs in Women
TUESDAY, April 1, 2025 (HealthDay News) -- The U.S. Food and Drug Administration granted marketing authorization for the first home-based, nonprescription diagnostic test for chlamydia, gonorrhea, and trichomoniasis in women, the agency announced Friday.
US authorizes first home test for three common sexually transmitted infections
The U.S. Food and Drug Administration on Friday granted authorization to market the first test that can be performed entirely at home for detecting three sexually transmitted infections (STIs).
MedPage Today
Anti-Aging, Acupuncture and Health NewsFDA OKs First At-Home Test for Chlamydia, Gonorrhea, and Trichomoniasis
(MedPage Today) -- The FDA on Friday granted marketing authorization to the first at-home test for diagnosing chlamydia, gonorrhea, and trichomoniasis in females. The so-called Visby Medical Women's Sexual Health Test requires no prescription...
Coverage Details
Bias Distribution
- 44% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
